Ocular Therapeutix director granted stock, options
Ocular Therapeutix director Richard L. Lindstrom, MD received new equity awards as board compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ocular Therapeutix director Richard L. Lindstrom, MD received new equity awards as board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, and 44,000 stock options with an exercise price of $8.74 per share expiring on June 9, 2036.
Both the RSUs and options vest 100% on the first anniversary of the grant date or, if earlier, immediately before the next annual meeting of stockholders, provided he continues to serve on the board. Following the RSU grant, he directly owns 260,933 common shares.
Insider Trade Summary
Grant/Award: 58,000 shares
Grant/Award
2 txns
Insider
LINDSTROM RICHARD L MD
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 14,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,000 contracts (Direct);
Common Stock — 260,933 shares (Direct)
Footnotes (2)
- F1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
- F2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Key Figures
RSU grant size: 14,000 shares
Option grant size: 44,000 options
Option exercise price: $8.74 per share
+2 more
5 metrics
RSU grant size
14,000 shares
Restricted stock units granted on June 10, 2026
Option grant size
44,000 options
Stock Option (Right to Buy) granted on June 10, 2026
Option exercise price
$8.74 per share
Exercise price for 44,000 stock options
Option expiration
June 9, 2036
Expiration date of stock options
Shares owned after grant
260,933 shares
Common stock directly owned following RSU grant
Key Terms
restricted stock units ("RSUs"), 2021 Stock Incentive Plan, Stock Option (Right to Buy), annual meeting of stockholders, +1 more
5 terms
restricted stock units ("RSUs") financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Incentive Plan financial
"RSUs under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
annual meeting of stockholders financial
"immediately prior to the next annual meeting of stockholders occurring after the grant date"
vest financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did OCUL director Richard Lindstrom report?
Director Richard L. Lindstrom, MD reported receiving equity awards, not open-market trades. He was granted 14,000 restricted stock units and 44,000 stock options as compensation for his board service at Ocular Therapeutix on June 10, 2026.
What are the terms of Richard Lindstrom’s new OCUL stock options?
Lindstrom received 44,000 stock options to buy Ocular Therapeutix common stock at an exercise price of $8.74 per share. These options expire on June 9, 2036 and vest in full after one year, subject to his continued board service.
When do Richard Lindstrom’s OCUL RSUs and options vest?
Both the 14,000 restricted stock units and 44,000 stock options vest 100% on the first anniversary of the June 10, 2026 grant date or, if earlier, immediately before the next annual stockholder meeting, assuming Lindstrom continues serving on the Ocular Therapeutix board.
Are Richard Lindstrom’s OCUL equity awards tied to continued board service?
Yes. Vesting of both the restricted stock units and stock options is conditioned on Lindstrom’s continued service on Ocular Therapeutix’s board. If he remains a director, they vest after one year or just before the next annual stockholder meeting, whichever occurs first.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates